Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
- Resource Type
- Article
- Source
- Infection; Oct2023, Vol. 51 Issue 5, p1273-1284, 12p, 1 Diagram, 4 Charts, 5 Graphs
- Subject
DISEASE progression DRUG efficacy STATISTICS CAUSES of death COVID-19 SARS-CoV-2 CONFIDENCE intervals IMMUNOCOMPROMISED patients RNA AMINES TREATMENT effectiveness COMPARATIVE studies HOSPITAL care DESCRIPTIVE statistics RESEARCH funding DATA analysis DRUG side effects PATIENT safety - Language
- ISSN
- 03008126